Výsledky vyhledávání - "Georgine E, de Greef"

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Autor: Georgine E. de Greef, Nancy Boeckx, Bronno van der Holt, Vincent H.J. van der Velden, Rik A. Brooimans, Ngoc M. Van, Gerrit Jan Schuurhuis, Jeroen G. te Marvelde, Erik Huys, J. Slomp, Angèle Kelder, Frank Preijers, Antoinette Heijs

Publikováno v: Leukemia Research, 76, 39-47. Elsevier Ltd.
Leukemia Research, 76, pp. 39-47
Leukemia Research, 76, 39-47

Flow-cytometric detection of now termed measurable residual disease (MRD) in acute myeloid leukemia (AML) has proven to have an independent prognostic impact. In a previous multicenter study we developed protocols to accurately define leukemia-associ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5cef9260e4328f1e12f9dd65ab9227a
https://pure.eur.nl/en/publications/9d31ce44-9625-41a1-b805-b997c3474bca

Zobrazit plný text záznamu

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study

Autor: Georgine E. de Greef, Vladimir Vucinic, Jeroen Janssen, Nicole Thuss, Eric Braakman, Eefke Petersen, Meriam Grootes, Jan J. Cornelissen, Bronno van der Holt

Publikováno v: Transfusion, 59(1), 316-324. Wiley-Blackwell Publishing Ltd
Transfusion

Background Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marrow niche. Study design and Methods in the prospective HOVON‐107 study (www.hovon.nl) 23 allogeneic HLA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f8925b51232f23377a51084c35fc7e
https://doi.org/10.1111/trf.15037

Zobrazit plný text záznamu

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

Autor: Eline M. P. Cremers, Saskia K. Klein, Petra Muus, Marian Stevens-Kroef, Georgine E. de Greef, Theresia M. Westers, Canan Alhan, Daniel Olde Weghuis, Pierre W. Wijermans, Sonia M Cunha, Najat ElIdrissi-Zaynoun, M Ron Schaafsma, Edo Vellenga, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Dana A. Chitu, Heleen Visser-Wisselaar, Joop H. Jansen

Publikováno v: Genes, Chromosomes and Cancer. 56:524-534

Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b0464314cf046abda92350ec5abc02
https://doi.org/10.1002/gcc.22455

Zobrazit plný text záznamu

Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor

Autor: Liane te Boome, Georgine E. de Greef, Ellen P. A. Kramer, Cynthia Huisman, Yavuz M. Bilgin, Erik A M Beckers, Alexandra J. Croockewit, Otto Visser, Paula F. Ypma, Tanja Netelenbos

Publikováno v: Transfusion. 55:1021-1027

BACKGROUND: Plerixafor in combination with granulocyte-colony-stimulating factor (G-CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G-CSF. In 2009 the Stem Cell Working Party of the Dutch-Belgian Cooperative T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37405a6ede763898af0420b68489815a
https://doi.org/10.1111/trf.12979

Zobrazit plný text záznamu

Cytarabine Dose for Acute Myeloid Leukemia

Autor: Bob, Löwenberg, Thomas, Pabst, Edo, Vellenga, Wim, van Putten, Harry C, Schouten, Carlos, Graux, Augustin, Ferrant, Pieter, Sonneveld, Bart J, Biemond, Alois, Gratwohl, Georgine E, de Greef, Leo F, Verdonck, Martijn R, Schaafsma, Michael, Gregor, Matthias, Theobald, Urs, Schanz, Johan, Maertens, Gert J, Ossenkoppele, M, Van Marwijk Kooy

Publikováno v: New England Journal of Medicine, 364(11), 1027-1036. Massachussetts Medical Society
New England journal of medicine, 364(11), 1027-1036. Massachussetts Medical Society
New England Journal of Medicine, 364(11), 1027-1036. MASSACHUSETTS MEDICAL SOCIETY
Lowenberg, B, Pabst, T, Vellenga, E, van Putten, W, Schouten, H C, Graux, C, Ferrant, A, Sonneveld, P, Biemond, B J, Gratwohl, A, de Greef, G E, Verdonck, L F, Schaafsma, M R, Gregor, M, Theobald, M, Schanz, U, Maertens, J & Ossenkoppele, G J 2011, ' Cytarabine Dose for Acute Myeloid Leukemia ', New England Journal of Medicine, vol. 364, no. 11, pp. 1027-1036 . https://doi.org/10.1056/NEJMoa1010222
New England Journal of Medicine, 364(11), 1027-1036. MASSACHUSETTS MEDICAL SOC

Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the convent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9cd9b92a79f76d4e77bf13394bd5eb
https://doi.org/10.1056/nejmoa1010222

Zobrazit plný text záznamu

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

Autor: Anne Hagemeijer, Clemens Mellink, Georgine E. de Greef, Shama L. van Zelderen-Bhola, Wim L.J. van Putten, Martine Jotterand, Aggie W. M. Nieuwint, Dimitri Breems, H. Berna Beverloo, Klasien B. J. Gerssen-Schoorl, Bob Löwenberg

Publikováno v: Journal of Clinical Oncology, 26(29), 4791-4797. American Society of Clinical Oncology
Journal of Clinical Oncology, 26(29), 4791-4797. AMER SOC CLINICAL ONCOLOGY
Breems, D A, Van Putten, W L J, De Greef, G E, Van Zelderen-Bhola, S L, Gerssen-Schoorl, K B J, Mellink, C H M, Nieuwint, A, Jotterand, M, Hagemeijer, A, Beverloo, H B & Löwenberg, B 2008, ' Monosomal karyotype in acute myeloid leukemia : A better indicator of poor prognosis than a complex karyotype ', Journal of Clinical Oncology, vol. 26, no. 29, pp. 4791-4797 . https://doi.org/10.1200/JCO.2008.16.0259
Journal of clinical oncology, 26(29), 4791-4797. American Society of Clinical Oncology

Purpose To investigate the prognostic value of various cytogenetic components of a complex karyotype in acute myeloid leukemia (AML). Patients and Methods Cytogenetics and overall survival (OS) were analyzed in 1,975 AML patients age 15 to 60 years.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49fa2eaa837892367cd4aaa5b127db09
https://doi.org/10.1200/jco.2008.16.0259

Zobrazit plný text záznamu

Plerixafor for stem cell mobilization: the current status

Autor: Georgine E. de Greef, Yavuz M. Bilgin

Publikováno v: Current Opinion in Hematology, 23(1), 67-71. Lippincott Williams & Wilkins

Purpose of review Nowadays, plerixafor is approved for patients who fail to mobilize sufficient CD34(+) cells for an autologous stem cell transplantation. Plerixafor is effective in the majority of these patients, who otherwise could not be treated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5969ecdc25df8e1443810eaebc56aee
https://pure.eur.nl/en/publications/ab58e8c3-a0b1-4533-9e0f-467131e55969

Zobrazit plný text záznamu

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies

Autor: Peter C. Huijgens, Matthias Theobald, Edo Vellenga, Bob Löwenberg, Emanuel Jacky, Leo F. Verdonck, Wim L.J. van Putten, Georgine E. de Greef, Marc Boogaerts

Publikováno v: British Journal of Haematology, 128(2), 184-191. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 128(2), 184-191. Wiley

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa179839addb3c8fe26275e4bc5b17d7
https://doi.org/10.1111/j.1365-2141.2004.05285.x

Zobrazit plný text záznamu

Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012

Autor: A.G. Dinmohamed, Georgine E. de Greef, Mojca Jongen-Lavrencic, Arjan A. van de Loosdrecht, Otto Visser, Pieter Sonneveld, Mirian Brink

Publikováno v: Dinmohamed, A G, van den Brink, M, Visser, O, Sonneveld, P, van de Loosdrecht, A A, Jongen-Lavrencic, M & de Greef, G E 2015, ' Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012 ', British Journal of Haematology, vol. 171, no. 3, pp. 436-439 . https://doi.org/10.1111/bjh.13414
British Journal of Haematology, 171(3), 436-439. Wiley-Blackwell
British Journal of Haematology, 171(3), 436-439. Wiley-Blackwell Publishing Ltd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bf17aafb7410dc4abf1b12a85a39232
https://research.vumc.nl/en/publications/51b4b872-0e37-4458-8a40-e42b7ff11c20

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání